» Articles » PMID: 29168173

The Role of Melatonin on Chemotherapy-induced Reproductive Toxicity

Overview
Specialties Pharmacology
Pharmacy
Date 2017 Nov 24
PMID 29168173
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Reproductive malfunctions after chemotherapy still are a reason of reducing fertility and need specialized intensive care. The aim of this review was to investigate the effect of melatonin on the reproductive system under threatening with chemotherapeutic drugs.

Methods: To find the role of melatonin in the reproductive system during chemotherapy, a full systematic literature search was carried out based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines in the electronic databases up to 17 April 2017 using search terms in the titles and abstracts. A total of 380 articles are screened according to our inclusion and exclusion criteria. Finally, 18 articles were included in this study.

Key Findings: It has been cleared that melatonin has bilateral effects on reproductive cells. Melatonin protects normal cells via mechanisms, including decrease in oxidative stress, apoptosis, inflammation and modulating mitochondrial function, and sexual hormones. Furthermore, melatonin with antiproliferative properties and direct effects on its receptors improves reproductive injury and function during chemotherapy. On the other hand, melatonin sensitizes the effects of chemotherapeutic drugs and enhances chemotherapy-induced toxicity in cancerous cells through increasing apoptosis, oxidative stress and mitochondrial malfunction.

Conclusions: The study provides evidence of the bilateral role of melatonin in the reproductive system during chemotherapy.

Citing Articles

Alleviating doxorubicin-induced reproductive toxicity: protective and androgenic effects of drone larvae on sperm morphology and hormonal balance.

Agan K, Kaya S, Agan A, Agyar-Yoldas P, Yoldas T, Ikinci-Keles A Toxicol Res. 2025; 41(2):149-165.

PMID: 40013081 PMC: 11850692. DOI: 10.1007/s43188-024-00270-z.


Melatonin for gastric cancer treatment: where do we stand?.

Rafiyan M, Tootoonchi E, Golpour M, Davoodvandi A, Reiter R, Asemi R Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(2):1265-1282.

PMID: 39287677 DOI: 10.1007/s00210-024-03451-7.


Methods for Overcoming Chemoresistance in Head and Neck Squamous Cell Carcinoma: Keeping the Focus on Cancer Stem Cells, a Systematic Review.

Bizzoca M, Caponio V, Lo Muzio L, Claudio P, Cortese A Cancers (Basel). 2024; 16(17).

PMID: 39272862 PMC: 11394389. DOI: 10.3390/cancers16173004.


Gynotoxic Effects of Chemotherapy and Potential Protective Mechanisms.

Markowska A, Antoszczak M, Markowska J, Huczynski A Cancers (Basel). 2024; 16(12).

PMID: 38927992 PMC: 11202309. DOI: 10.3390/cancers16122288.


Melatonin as a promising therapeutic intervention for restoring ovarian function in letrozole-induced polycystic ovary syndrome rats.

Basheer M, Bhat A, Hajam Y, El-Saber Batiha G, Ataya F, Fouad D Heliyon. 2023; 9(11):e21237.

PMID: 38027664 PMC: 10643099. DOI: 10.1016/j.heliyon.2023.e21237.